These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38249344)
41. To Investigate the Clinical Efficacy and Potential Mechanism of Tongxinluo Capsules in Preventing Coronary Restenosis Based on Meta-Analysis and Network Pharmacology Analysis. Wei WX; Jiang YH Evid Based Complement Alternat Med; 2023; 2023():7985459. PubMed ID: 36743461 [TBL] [Abstract][Full Text] [Related]
47. [Network Meta-analysis of efficacy and safety of oral Chinese patent medicines combined with conventional western medicine in treatment of hypertension]. Ji ZC; Lin SS; Hu HY; Sheng XD; Yang FW; Wang XL Zhongguo Zhong Yao Za Zhi; 2022 Apr; 47(7):1955-1988. PubMed ID: 35534266 [TBL] [Abstract][Full Text] [Related]
48. The efficacy of Chinese herbal medicines on acute coronary syndrome with renal insufficiency after percutaneous coronary intervention. Zhang DW; Wang SL; Wang PL; Du JP; Gao ZY; Wang CL; Xu H; Shi DZ J Ethnopharmacol; 2020 Feb; 248():112354. PubMed ID: 31689480 [TBL] [Abstract][Full Text] [Related]
49. A summary and evaluation of current evidence for myocardial infarction with Chinese medicine. Wang Y; Xiao L; Mu W; Yu HL; Zhang S; Tian GH; Shang HC Chin J Integr Med; 2017 Dec; 23(12):948-955. PubMed ID: 29079906 [TBL] [Abstract][Full Text] [Related]
50. Tongxinluo capsule as supplementation and cardiovascular endpoint events in patients with coronary heart disease: A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials. Lv J; Liu S; Guo S; Gao J; Song Q; Cui X J Ethnopharmacol; 2022 May; 289():115033. PubMed ID: 35091010 [TBL] [Abstract][Full Text] [Related]
51. The effectiveness and safety of Chinese Patent Medicines based on syndrome differentiation in patients following percutaneous coronary intervention due to acute coronary syndrome (CPM trial): A nationwide Cohort Study. Bai R; Yang Q; Xi R; Che Q; Zhao Y; Guo M; Dong G; Gao Z; Fu C; Wang P; Gu F; Du J; Zhang D; Duan W; Li L; Shi D Phytomedicine; 2023 Jan; 109():154554. PubMed ID: 36610159 [TBL] [Abstract][Full Text] [Related]
52. Coronary collaterals and risk for restenosis after percutaneous coronary interventions: a meta-analysis. Meier P; Indermuehle A; Pitt B; Traupe T; de Marchi SF; Crake T; Knapp G; Lansky AJ; Seiler C BMC Med; 2012 Jun; 10():62. PubMed ID: 22720974 [TBL] [Abstract][Full Text] [Related]
53. Ivermectin for preventing and treating COVID-19. Popp M; Reis S; Schießer S; Hausinger RI; Stegemann M; Metzendorf MI; Kranke P; Meybohm P; Skoetz N; Weibel S Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015017. PubMed ID: 35726131 [TBL] [Abstract][Full Text] [Related]
54. Association of Elevated Plasma Homocysteine Level with Restenosis and Clinical Outcomes After Percutaneous Coronary Interventions: a Systemic Review and Meta-analysis. Zhang Z; Xiao S; Yang C; Ye R; Hu X; Chen X Cardiovasc Drugs Ther; 2019 Jun; 33(3):353-361. PubMed ID: 30778807 [TBL] [Abstract][Full Text] [Related]
55. Comparative Efficacy of Oral Chinese Patent Medicine for Chronic Prostatitis/Chronic Pelvic Pain Syndrome With Sexual Dysfunction: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Zhang Y; Ma H; Nan T; Li Y; Zheng W; Zhou Z; Gong X Front Pharmacol; 2021; 12():649470. PubMed ID: 34040523 [No Abstract] [Full Text] [Related]
56. The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials. Liu Z; Chen Y; Jie C; Wang J; Deng Y; Hou X; Li Y; Cai W Front Endocrinol (Lausanne); 2023; 14():1144290. PubMed ID: 37077355 [TBL] [Abstract][Full Text] [Related]
58. Efficacy of Drug-Coated Balloon Approaches for Zhong PY; Ma Y; Shang YS; Niu Y; Bai N; Wang ZL Front Cardiovasc Med; 2022; 9():899701. PubMed ID: 35800174 [TBL] [Abstract][Full Text] [Related]
59. Interventions to improve sanitation for preventing diarrhoea. Bauza V; Ye W; Liao J; Majorin F; Clasen T Cochrane Database Syst Rev; 2023 Jan; 1(1):CD013328. PubMed ID: 36697370 [TBL] [Abstract][Full Text] [Related]
60. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction. Su Q; Nyi TS; Li L Cochrane Database Syst Rev; 2015 May; 2015(5):CD009503. PubMed ID: 25985145 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]